Skip to content
Triangle logo TriangleGet started
← Study library

NCT03168438 · REGISTRY CONDITION SEARCH

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1
Status at capture
TERMINATED
Registry last update
2022-01-11

This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

→

outcome · POSTED

Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only

→

outcome · POSTED

Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline

→

outcome · POSTED

Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to Baseline

→

outcome · POSTED

Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline

→

outcome · POSTED

Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Time to Response

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Maximum Persistence (Cmax) of GSK3377794

→

outcome · POSTED

Time to Maximum Persistence

→

outcome · POSTED

Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Age \>=18 years of age or older on the date of signing informed consent. * Histologically confirmed diagnosis of secretory multiple myeloma with myeloma markers at levels defined in the protocol. * Documented diagnosis of relapsed and refractory multiple myeloma (RRMM) (at least 3 prior regimens and responsive to at least 1, and refractory to most recent prior therapies, which must have included one or more than one drug from each of the following drug classes: an immunomodulatory imide drug (IMiD), proteasome inhibitor, alkylator (unless the participant is ineligible or contraindicated to receive an alkylator), CD 38 monoclonal antibody, and glucocorticoid as separate lines or a combined line of therapy.- Left ventricular ejection fraction (LVEF) \>= 50%. Lower LVEF (\>= 40%) permissible if formal cardiologic evaluation reveals no evidence for clinically significant functional impairment. * Meets protocol criteria for patients who have previously received checkpoint inhibitors or other immuno-oncology agents. * ECOG Performance Status 0 or 1. * Participant is HLA-A\*02:01, HLA-A\*02:05, and/or HLA-A\*02:06 positive as determined by a designated central laboratory. * Participant has confirmed sufficient expression of NY-ESO-1 and/or LAGE-1a as determined by a designated central laboratory. * In the Investigator's opinion, the participant is fit for cell collection. * Participant has adequate organ function and cell counts as described in the protocol. * Participants previously treated with BCMA therapy (BCMA chimeric antigen receptor (CAR)-T, antibody-drug conjugate (ADC), or other type of BCMA-targeted therapy) must have progressed from this therapy prior to attending the Baseline visit prior to beginning lymphodepletion. * Contraception use by male and female participant meets protocol requirements. Exclusion Criteria: * Has only plasmacytomas, plasma cell leukemia, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), non-secretory myeloma or primarily amyloidosis. * Previously received anti- programmed death (PD)-1, anti-PD-ligand (L)1, or anti-PD-L2 inhibitor. * Previously participated in Merck pivotal trial NCT02576977: Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab in Refractory or RRMM. * Had a prior allogeneic stem cell transplant. * Has ongoing toxicity from previous anticancer therapy. * Had a major surgery within 4 weeks prior to enrollment. * Has history of allergic reactions to fludarabine, cyclophosphamide or agents similar to fludarabine, cyclophosphamide or other agents used in the study. * Known history of myelodysplasia. * Current active liver or biliary disease. * Known history of chronic active hepatitis or liver cirrhosis. * Participant has an active viral infection. * History of severe immune disease, including non-infectious pneumonitis, requiring steroids or other immunosuppressive treatments. * Active immune-mediated diseases. * Prior or active demyelinating disease. * Evidence or history of significant cardiac disease. * Evidence or history of other significant, hepatic, renal, ophthalmologic, psychiatric, or gastrointestinal disease. * Participants with concomitant second malignancies (except adequately treated non-melanomatous skin cancers, carcinoma in situ of the breast, treated superficial bladder cancer or prostate cancer, or in situ cervical cancers ) not in complete remission. * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may be eligible. * Active bacterial or systemic viral or fungal infections. * Pregnant or breastfeeding. * Cannot meet washout periods for prior radiotherapy, chemotherapy or other protocol-specified therapies. * More than 2 years have passed since the participant's last leukapheresis collection.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
    intervention Names
    1. Drug: Letetresgene autoleucel
    2. Drug: Fludarabine
    3. Drug: Cyclophosphamide
    label
    Arm 1: Letetresgene autoleucel (GSK3377794)
    type
    EXPERIMENTAL
  2. description
    Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy, followed by pembrolizumab 200 mg every 3 weeks.
    intervention Names
    1. Drug: Letetresgene autoleucel with pembrolizumab
    2. Drug: Fludarabine
    3. Drug: Cyclophosphamide
    4. Drug: Pembrolizumab
    label
    Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm 1: Letetresgene autoleucel (GSK3377794)
    description
    Letetresgene autoleucel (GSK3377794) as an IV infusion
    name
    Letetresgene autoleucel
    type
    DRUG
  2. arm Group Labels
    1. Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab
    description
    Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
    name
    Letetresgene autoleucel with pembrolizumab
    type
    DRUG
  3. arm Group Labels
    1. Arm 1: Letetresgene autoleucel (GSK3377794)
    2. Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab
    description
    Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
    name
    Fludarabine
    type
    DRUG
  4. arm Group Labels
    1. Arm 1: Letetresgene autoleucel (GSK3377794)
    2. Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab
    description
    Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
    name
    Cyclophosphamide
    type
    DRUG
  5. arm Group Labels
    1. Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab
    description
    Pembrolizumab is available as an IV infusion
    name
    Pembrolizumab
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
6
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    An AE is any untoward medical occurrence in a participant or clinical investigation participant who received a study treatment and the event need not necessarily have a causal relationship with study treatment. An SAE is any AE that results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in a persistent or significant disability; is a congenital anomaly/birth defect; is clinically significant or requires intervention to prevent one of the outcomes listed before.
    measure
    Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
    time Frame
    Up to 108 weeks
  2. description
    The following toxicities were considered to be treatment limiting toxicities: any \>=Grade 4 AE; Grade 3 non-infectious pneumonitis and any other Grade 3 AE (excluding pneumonitis), that did not improve to Grade 2 within 7 days after onset despite medical management and supportive care. Exceptions included the following: Grade 3 or 4 leukopenia, lymphopenia, neutropenia, or febrile neutropenia; Grade 3 or 4 thrombocytopenia not associated with significant bleeding; Grade 3 anemia; Grade 4 cytokine release syndrome (CRS) or toxicities related to CRS that resolved to Grade \<=2 within 7 days; other Grade 3 laboratory abnormality determined to be not clinically significant by the Investigator; Grade 3 or 4 fever and chills; Grade 3 or 4 hypoalbuminemia or abnormal electrolytes that responded to supplementation/correction; AE related to the cancer or its progression.
    measure
    Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only
    time Frame
    Up to 3 weeks
  3. description
    Blood samples were collected for the assessment of following clinical chemistry parameters: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine, potassium, magnesium, phosphate, sodium and calcium. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.
    measure
    Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline
    time Frame
    Up to 108 weeks
  4. description
    Blood samples were collected for the assessment of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. Laboratory parameters were graded according to NCI-CTCAE version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.
    measure
    Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to Baseline
    time Frame
    Up to 108 weeks
  5. description
    Blood samples were collected for the assessment of following coagulation parameters: prothrombin time and partial thromboplastin time (PTT). A laboratory value that is outside the normal range is considered either high abnormal (value above the upper limit of the normal range) or low abnormal (value below the lower limit of the normal range). Participants were counted twice if the participant had values in 'Decreased to low' and 'Increased to high' during the post-Baseline period. Data for worst case post Baseline is presented.
    measure
    Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline
    time Frame
    Up to 108 weeks
  6. description
    ECG was recorded using an ECG machine that automatically calculated the heart rate and measured PR, RR, QRS and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Data for number of participants with abnormal clinically significant ECG findings for worst case post-Baseline has been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
    measure
    Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings
    time Frame
    Up to 108 weeks
secondary Outcomes
  1. description
    Overall response rate is defined as the percentage of participants with a best overall response (BOR) of confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) Response Criteria (2016); where, PR: \>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 milligrams (mg) per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or sCR: CR as defined by normal free light chain (FLC) ratio and absence of clonal cells by immunohistochemistry. Confidence intervals were calculated using the exact (Clopper-Pearson) method.
    measure
    Overall Response Rate
    time Frame
    Up to 108 weeks
  2. description
    Time to response is defined as the time interval (in months) from T-cell infusion to initial date of documented confirmed response (PR or better) in the subset of participants who showed a confirmed BOR of PR or better by Investigator assessment per IMWG (2016).
    measure
    Time to Response
    time Frame
    Up to 108 weeks
  3. description
    Duration of response is defined as the interval between the initial date of the confirmed response (sCR, CR, VGPR, or PR) and the initial assesment date of confirmed progressive disease or death among participants with a confirmed response per IMWG (2016).
    measure
    Duration of Response
    time Frame
    Up to 108 weeks
  4. description
    Progression Free Survival is defined as the interval between the date of T-cell infusion and the initial assessment date of confirmed progressive disease as assessed by the investigator per IMWG (2016) or date of death. Progressive disease is defined as an increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>=0.5 grams per deciliter (g/dL); Serum M-protein increase \>=1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>=200 mg per 24 hours).
    measure
    Progression-free Survival
    time Frame
    Up to 108 weeks
  5. description
    Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in deoxyribonucleic acid (DNA) extracted from peripheral blood mononuclear cell (PBMC).
    measure
    Maximum Persistence (Cmax) of GSK3377794
    time Frame
    Up to 108 weeks
  6. description
    Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.
    measure
    Time to Maximum Persistence
    time Frame
    Up to 108 weeks
  7. description
    Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.
    measure
    Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])
    time Frame
    Up to Day 28
Full study description
brief Summary
This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.
Source references
references
  1. citation
    Nishihori T, Hoffman JE, Huff A, Kapoor GS, Eleftheriadou I, Zajic S, Urbano A, Suchindran S, Chisamore M, D'Souza JW, Faitg T, Rapoport AP. Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma. Blood Adv. 2023 Apr 11;7(7):1168-1177. doi: 10.1182/bloodadvances.2022008460.
    pmid
    36534160
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-d1fa0737434d9296e26d
      requested nct id
      NCT03168438
      primary nct id
      NCT03168438
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      3de2a08b357c71e38929ce58d54106f10a30249226d455ae8ea17f24176c7282
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-d1fa0737434d9296e26d
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03168438
      occurrences
      1. context exact
        NCT03168438
        end
        11
        exact text
        NCT03168438
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/717/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      6946fe3ff50e484c9a081dde6f4b5a0c2b3baf05a24bc58855559302d0ccd73d

    Preserved source evidence · Not medical advice